Abstract: Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to form rdsRNs de novo.

Abstract: The present invention relates to novel synthetic or natural peptides for use in treating viral or parasitic infections or in the treatment of tumors. The peptides of the present invention are less than 30 amino acids in size, preferably less than 20 amino acids, in particular 15 to 20 amino acids, and in vitro the peptides specifically bind a type 2A protein phosphatase holoenzyme or one of its subunits. The invention also relates to a method for identifying said peptides, and to their uses.

Abstract: This invention relates to a method of modulating the expression of a target gene in an organism comprising administering an iRNA agent, wherein the iRNA comprises at least one 2?-deoxy-2?-fluoro (2?-F) nucleotide in the antisense strand and at least one modified nucleotide in the sense strand. The invention also relates to compositions comprising a single-stranded oligonucleotide that contains at least one 2?-deoxy-2?-fluoro (2?-F) nucleotide. siRNA molecule containing these oligonucleotides have decreased immunogenicity.

Abstract: An object of the present invention is to provide an RNAi control system using an RNA-protein interaction motif. The present invention provides an shRNA comprising: a guide strand having a sequence complementary to a target sequence; a passenger strand which forms a duplex with the guide strand; and a linker strand which links the guide strand and the passenger strand, wherein the linker strand comprises an RNP-derived protein-binding motif sequence. The present invention also provides an RNAi control system comprising: the shRNA; and an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.

Abstract: The subject invention pertains to a conjugate comprising: (a) a first region comprising the homeodomain of antennapedia or a variant thereof; and (b) a second region not naturally associated with the first region. In one embodiment, the second region of the conjugate comprises a protein of at least 100 amino acids.

Abstract: A medical or dental material can be prepared by using, as an active ingredient, at least one of a protamine, and derivatives thereof and hydrolysates thereof, or a complex of at least one of a protamine, and derivatives thereof and hydrolysates thereof with an anionic high molecular weight compound. As a result, an antibacterial agent against periodontal disease-causing bacteria can be provided, which is highly safe without concern of a side effect. A medical or dental material can be also provided, which exhibits antimicrobial activity on periodontal disease-causing bacteria and additionally has insolubility in water and good formability.

Abstract: Methods, systems and kits are provided for detecting and quantifying multiple immunogens in a sample via consecutive addition of quantifiable extenders to immunogen bound complexes of immunogen binding agent attached to a DNA containing an RNA polymerase promoter.

Abstract: The invention provides compositions comprising a TERT-RMRP or TERT-RNA complex and methods of treating subjects with genetic diseases in which gene silencing is either increased by administering the compositions of the invention or decreased by administering an inhibitor of the RNA-dependent RNA polymerase (RdRP) activity of these compositions. Moreover, the invention provides methods of screening for agonists and antagonists of RdRP activity and TERT-RMRP complex formation. Finally, the invention provides a method of identifying a RNA molecule that forms a complex with a TERT polypeptide and has RdRP activity.

Abstract: The invention relates to the use of peptides, proteins, and other oligomers to provide a means by which normally quenched nanoparticle fluorescence may be recovered upon detection of a target molecule. Further, the inventive technology provides a structure and method to carry out detection of target molecules without the need to label the target molecules before detection. In another aspect, a method for forming arbitrarily shaped two- and three-dimensional protein-mediated nanoparticle structures and the resulting structures are described. Proteins mediating structure formation may themselves be functionalized with a variety of useful moieties, including catalytic functional groups.

Abstract: The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.

Abstract: The present invention relates to methods of delivering nucleic acids into cells using a nucleic acid binding molecule containing a multimeric or spacer-incorporated protein transduction domain (PTD). The invention also relates to novel compositions that contain a nucleic acid complexed or conjugated with a nucleic acid binding molecule. The nucleic acid binding molecule may contain a multimeric or spacer-incorporated PTD, and may further contain a nucleic acid binding region. The nucleic acid complexes or conjugations of the present invention may be employed to inhibit expression of a target gene, and/or determine the function of a target gene.

Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.

Abstract: A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). From the enriched library, two sdAbs were selected, sequenced, subcloned, and expressed as fusion proteins with c-myc-His5 tags. Similarly as phage-displayed sdAbs, these soluble tagged sdAbs were shown to selectively bind to HCEC and to transmigrate across in vitro human blood-brain barrier (BBB) model. In contrast to an unrelated llama sdAb, these sdAbs were also detected in the brain after i.v. injection into mice. These small (˜13 kDa) antibody fragments have essential characteristics of brain-specific delivery vectors and can be used to facilitate drug transport across the BBB.

Abstract: The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.

Abstract: The present invention provides an immunogenic composition comprising at least one antigen delivery particle and at least one antigen, wherein the antigen and antigen delivery particle are linked using an intermediate linker.

Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.

Abstract: Disclosed herein are methods of detecting non-natural amino acids and polypeptides that include at least one non-natural amino acid. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of functionalities, including but not limited to oxime, carbonyl, and/or hydroxylamine groups. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, and methods for detecting such polypeptides.

Abstract: The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes.

Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immuno-conjugates. The invention also relates to diagnostic and therapeutic methods and kits.

Abstract: Compositions and methods for improved delivery of macromolecules into eukaryotic cells are provided. Fusogenic peptides from fusion proteins of non-enveloped viruses enhance the efficiency of transfection of eukaryotic cells mediated by transfection agents such as cationic lipids, polycationic polymers such as PEI and dendrimers. These fusogenic peptides are used as part of a transfection complex that efficiently delivers a macromolecule, for example, a nucleic acid, into a eukaryotic cell. Novel cationic lipids and compositions of cationic lipids also are provided that may be used for the introduction of macromolecules such as nucleic acids, proteins and peptides into a variety of cells and tissues. The lipids can be used alone, in combination with other lipids and/or in combination with fusogenic peptides to prepare transfection complexes.

Abstract: The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.

Abstract: The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.

Abstract: The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.

Abstract: The present invention discloses a nasopharyngeal cancer malignancy biomarker and a method thereof, wherein relative hnRNP K expression is used to evaluate the malignancy of nasopharyngeal cancer. The biomarker of the present invention assists the currently-existing inspections to find out cancer in the early stage and realize early diagnosis and early therapy. The present invention also functions as an effective indicator to monitor the metastasis and relapse of nasopharyngeal cancer.

Abstract: Novel methods for enzymatic synthesis of nucleic acid chains and the substrates for the same are disclosed. The methods are based on a step-wise enzymatic reaction. The sequencing of nucleic acids is an example of the use of the claimed methods.

Abstract: The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. The immunostimulating agent according to the invention and the vaccine according to the invention are employed in particular against infectious diseases or cancer diseases.

Abstract: We use the Tus-Ter interaction to enable the utilization of nucleic acid analytical methodologies for proteins. We also use the Tus-Ter interaction to make polymers and oligomers that have a nucleic acid backbone with protein functionalities. These methods are useful for molecular modeling, for efficiently running enzymatic pathway reactions, and for analyzing presence and/or amount of particular proteins.

Abstract: To improve the activity of a Koji mold protease in a solid or liquid culture medium in the production of foods (e.g., a seasoning), pharmaceuticals (e.g., a digestive agent), protease for use in a detergent and the like. Disclosed are a recombinant vector having capability of increasing the secretion of the Koji mold protease, a Koji mold which is transformed with the vector and has an increased expression of a gene for a protease or an increase secretion of the same, a method for the production of a protease by using the transformed Koji mold, and the like.

Abstract: This document includes methods and materials for enriching and detecting cancer markers. For example, this document includes methods and materials for enriching methylated mammalian nucleic acid from stool samples.

Abstract: Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

Abstract: To provide a prophylactic/therapeutic agent for neurodegenerative diseases (such as polyglutamine diseases), the agent containing an HMGB family protein or a derivative thereof, such as a protein according any one of (a) and (b) below: (a) a protein having the amino acid sequence of SEQ ID NO: 2, 4, 6 or 8; and (b) a protein having an amino acid sequence resulting from deletion, substitution, addition or insertion of one or more amino acids in the amino acid sequence of SEQ ID NO: 2, 4, 6 or 8 and having binding activity to an abnormal polyglutamine protein produced in a neurodegenerative disease.

Abstract: A DNA polymerase reaction system which provides high DNA polymerase activity even at a high temperature and at a high salt concentration. A DNA polymerase reaction system that is constructed from a DNA polymerase, a clamp, and a clamp loader without intein sequence, the DNA polymerase being from Pyrococcus horikoshii, a hyperthermophilic archaeon.

Abstract: Compositions for countering immune attenuating/suppressive pathways comprise targeting agents or aptamer targeted RNAi-mediated gene silencing (siRNA/shRNA). These compositions have broad applicability in the treatment of many diseases.

Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

Abstract: Nucleic acid compositions, methods of making and using such compositions that comprise modular functional groups that can be configured to provide desired functionality to different nucleotide types through a swappable and preferably non-covalent linkage component. Such compositions are useful in a variety of applications including nucleic acid analyses.

Abstract: An isolated nucleic acid sequence of BRAF35 and polypeptides encoded thereby are provided, as well as a multiprotein complex, and an antibody capable of binding selectively to the BRAF35 protein. Related agents and compositions which modulate interaction between BRCA2 and BRAF35 and methods of their use for screening for the BRCA2 protein, suppressing tumors and identifying DNA damage in cells indicative of a risk for developing cancer are also provided.

Abstract: Provided is a structure designed for adsorption, which is suitable for removing dioxin and dioxin-like substances from leachate and ground water from polluted soils or garbage, washing effluent from garbage incinerators and so on that contain DNA intercalators, particularly, dioxin and dioxin-like substances. The structure designed for adsorption is a structure designed for adsorption having an adsorbing layer containing, as a constituent, a DNA complex containing a DNA-binding protein, DNA including double strand DNA and a carrier, which can selectively remove DNA intercalators with high efficiency from water, gas and so on containing them.

Abstract: Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.

Abstract: The invention provides ssDNA-binding proteins from three species of archaeons, Methanococcus jannaschii, Methanobacter theromoautotrophicum, and Archaeoglobus fulgidus, as well as the ability to identify ssDNA-binding proteins from other archaeons. The proteins help render DNA more accessible to DNA polymerase and are robust reagents for a variety of biotechnical processes, including PCR. The invention further provides nucleic acids encoding such proteins, vectors for transfecting host cells, host cells comprising the vectors, and methods of using the proteins.

Abstract: This invention provides Sso7-polymerase conjugates that exhibit improved activity in a polymerase reaction.

Abstract: A method for the identification of novel compounds that interact and stabilize the ligand binding domain of estrogen-related receptor gamma (ERR?), a methodology for producing diffraction quality crystal structures in the presence of antagonist and agonist ligands, including Bisphenol A, and the identification of novel biologically-active compounds that have an effect on the transcriptional-activating activity of ERR? are disclosed.

Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.

Abstract: The present invention provides a nucleic acid polyhedron having a moiety associated therewith together with methods of making the nucleic acid polyhedron.

Abstract: The present invention provides a tumor marker and a method capable of identifying the morbidity of colon cancer. A tumor marker including a protein identified from a colon cancer tissue. A method for identify the morbidity of colon cancer using the tumor marker. The method includes: measuring the level of the protein in a sample derived from a person of interest who should be examined to identify the morbidity of colon cancer; and comparing the measured level to the normal level of the protein, wherein a higher or lower measured level than the normal level is used as one indicator indicating that there is a high possibility that the person of interest has colon cancer.

Abstract: The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain.

Abstract: The invention relates to new nucleic acid sequences of the family of tumour-suppressing genes related to the gene for the p53 protein, and to the corresponding protein sequences.

Abstract: Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1.

Abstract: This invention provides for an improved generation of novel nucleic acid modifying enzymes. The improvement is the fusion of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalytically modify the nucleic acid.

Abstract: The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.